Jaguar Health, Inc. — Investor Relations & Filings

Jaguar Health, Inc. is a commercial-stage pharmaceutical company that discovers, develops, and commercializes novel, proprietary, plant-based prescription medicines for both human and animal health. The company's primary focus is on addressing gastrointestinal (GI) diseases. Its core product, crofelemer, is a botanical drug sustainably derived from the Croton lechleri tree. For human health, crofelemer is in a Phase 3 clinical trial (OnTarget) for the preventative treatment of cancer therapy-related diarrhea and is also being studied for rare diseases like short bowel syndrome. In the animal health market, the company commercializes Canalevia-CA1, a prescription treatment for chemotherapy-induced diarrhea in dogs. Jaguar Health's pipeline spans multiple stages of development, leveraging its expertise in sustainably derived, plant-based therapeutics.